PHS 398 (Rev. 9/04), Biographical Sketch Format Page
Total Page:16
File Type:pdf, Size:1020Kb
Principal Investigator/Program Director (Last, First, Middle): PI Name Roshan Cools BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Cools, Roshan Professor of Cognitive Neuropsychiatry eRA COMMONS USER NAME Cools EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) DEGREE INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY (if applicable) University of Groningen, The Netherlands M.Sc.(equiv) 1993 Experimental Psychology University of Cambridge, UK M.Phil. 1999 Experimental Psychology University of Cambridge, UK Ph.D. 2003 Experimental Psychology A. Personal Statement I have a broad background in psychology and cognitive neuroscience, with specific training and expertise in the neurochemistry of cognitive control and decision making, combining psychopharmacology, pharmacological fMRI and PET to advance our understanding of the role of the major ascending neuromodulators, such as dopamine and serotonin, in the cognitive and motivational control of behaviour. As PI or co-Investigator on several university- and NWO-funded grants, I laid the groundwork for the proposed research by establishing a key role for striatal dopamine in learning and cognitive control. B. Positions and Honors. Appointments 2002-2007 Research Fellow, University of Cambridge UK 2003-2005 Visiting Research Fellow, University of California, Berkeley 2007-present Principal Investigator, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University 2011-present Professor of Cognitive Neuropsychiatry, Dept of Psychiatry, Radboud university medical centre 2014-present Member, (Government) Advisory Council for Science and Technology Policy, NL Professional Memberships 2017 Member, VIDI award selection committee (Social Sciences), NWO, NL 2016 – present Member, Academia Europaea (Section Behavioural Sciences) 2012 – present Member, Board of the Rathenau Institute (research, debate on Science and Technology), NL 2010 & 2014 Member, Rubicon grant selection Committee (Social Sciences), NWO, NL 2011 – present Member, Advisory Council Attention and Performance, US 2012 – 2014 Contributor to Research Network “A Roadmap on Mental Health Research in Europe” 2011, 2014, 2017 Member, PI Selection Committee, Radboudumc, NL 2008 - 2013 Member, Steering Committee of 1 of 4 Themes (‘Perception, Action and Control’) at Donders Institute, Radboud University, NL 2008 – present Member, Education Committee, Radboud University, NL 2008 – 2012 Member, Research Infrastructure Committee, Radboud University, NL 2013 – present Fellow, Association for Psychological Science, UK 2003 – present Member, Society for Neuroscience, US 2003 – present Member, Cognitive Neuroscience Society, US Commissions of Trust 2017 – now Reviewing Editor, Journal of Neuroscience 2010 - now Active Editor, Journal of Cognitive Neuroscience 2014 - now Member, Editorial Board Royal Society Open Science PHS 398/2590 (Rev. 05/01) Page Biographical Sketch Format Page Principal Investigator/Program Director (Last, First, Middle): PI Name 2014 - now Member, Editorial Board Current Opinion in Behavioral Sciences 2014 - now Member, Editorial Board Motivation Science 2012 – 2014 Associate Editor, special issue Frontiers Behavioral Neuroscience 2009 – 2015 Consulting Editor, Cognitive, Affective, & Behavioral Neuroscience Awards and Honors 1998 MSc degree with Cum Laude 1998-1999 Dutch-British Partnership Award, Cambridge UK 1998-2001 Cambridge European Trust Award, UK 1999-2002 CD Marsden Studentship, Parkinson’s Disease Society of the UK 1999-2002 Mary Ann Eward Studentship, Newnham College, Cambridge UK 2002-2006 Junior Research Fellowship, St John’s College, Cambridge UK 2002-2006 Royal Society Dorothy Hodgkin Research Fellowship, University of Cambridge UK 2002 Human Frontiers Longterm Fellowship (declined) 2006-2007 Royal Society University Research Fellowship, University of Cambridge UK 2008 Vidi award from the Netherlands Organization for Scientific Research 2011 Radboud Science Award for best research at Radboud University 2012 Young Investigator Award of the Cognitive Neuroscience Society 2012 James McDonnell Scholar Award 2015 Vici award from the Netherlands Organization for Scientific Research 2017 KNAW-Ammodo Award C. Contribution to Science I study the brain mechanisms of motivation and cognition by combining cognitive neuroscience with psychopharmacology, focusing on dopamine and serotonin. A strength of our group is the interventional nature of our work, which often involves manipulating the brain through pharmacological, electrical or psychological means in health and disease. The work is motivated by mechanistic questions about motivation and cognition. How do we motivate ourselves to exert cognitive control? How do we maximize reward? We leverage knowledge about dopamine and serotonin and combine the use of neurochemical PET, psychopharmacological fMRI, (computational) model-based analyses and trans-diagnostic patient work to resolve these questions. We hope to contribute to resolving a major problem in neurology and psychiatry: the huge variability in treatment efficacy. Cognitive effects of Parkinson’s disease In my earliest work I studied effects of dopaminergic medication on learning and control in patients with Parkinson’s disease. These series of experiments provided empirical evidence for, among other things, contrasting effects of medication depending on task demands, which led us to advance the ‘dopamine overdose hypothesis’ (Cools et al., 2001 Cereb Cortex; Cools, 2006 NBR). This and subsequent evidence (Smittenaar et al., 2014; Cools et al., 2010) inspired novel theoretical work on dopamine’s role in behavior (Frank, 2005 J Cogn Neurosci; Frank et al., 2004 Science; Collin and Frank, 2014 Psych Rev) as well as novel recent work on the role of inhibitory control mechanisms in interrupting cognition (Wessel and Aron, 2017 Neuron). I continue to study Parkinson’s disease, in order to refine and revise the dopamine overdose hypothesis, clarifying why not every patients develops the severe psychiatric side effects, such as ICD, after starting medication. Selected publications: 1. Cools R, Barker RA, Sahakian BJ, Robbins TW (2001). Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 11:1136-1143. 2. Cools R, Barker RA, Sahakian BJ, and Robbins TW (2001). Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain 124:2503-2512. 3. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002) Dopaminergic modulation of high-level cognition in Parkinson’s disease: The role of prefrontal cortex revealed by PET. Brain 125: 584-594. 4. Cools R, Barker R A, Sahakian B J, Robbins T W (2003). L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia 41:1431- 1441. PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page 6 Continuation Format Page Principal Investigator/Program Director (Last, First, Middle): PI Name 5. Cools R, Robbins TW (2004). Chemistry of the Adaptive Mind. Philos Transact Ser A Math Phys Eng Sci 362 (1825): 2871-2888. 6. Cools R (2006) Dopaminergic modulation of cognitive function – Implication for L-DOPA therapy in Parkinson’s disease. Neurosci Biobehav Rev 30 (1):1-34. 7. Cools R, Altamirano L, D’Esposito M (2006). Reversal learning in Parkinson’s disease depends on medication status and outcome valence. Neuropsychologia 44 (10):1663-1673 8. Cools R, Lewis SGJ, Clark L, Barker RA, Robbins TW (2007). L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson’s disease. Neuropsychopharmacology 32 (1): 180- 189. 9. Cools R, Miyakawa A, Sheridan M, D'Esposito M (2010). Enhanced frontal function in Parkinson's disease. Brain 133:225-33. 10. De Wit S, Barker RA, Dickinson A, Cools R (2011). Habitual versus goal-directed action control in Parkinson disease. J Cogn Neurosci. 23(5):1218-1229 [5.7] 11. Smittenaar P, Chase HW, Aarts E, Nusselein B, Bloem BR, Cools R (2012). Decomposing effects of dopaminergic medication in Parkinson’s disease on probabilistic action selection: learning or performance? Eur J Neurosci 35(7):1144-51 [3.9] 12. Aarts E, Nusselein AA, Smittenaar P, Helmich RC, Bloem BR, Cools R (2014). Greater striatal s disease are associated with better task-switching but worse reward׳responses to medication in Parkinson performance. Neuropsychologia 62:390-7 13. Robbins TW, Cools R (2014). Cognitive Deficits in Parkinson’s Disease: A Cognitive Neuroscience Perspective. Movement Dis 29:597:607 14. Timmer MHM, Sescousse G, Van der Schaaf ME, Esselink RAJ, Cools R (in press). Reward learning deficits in Parkinson’s disease depend on depression. Psychol Med Reversal learning In a second line of work, I have introduced a paradigm for assessing the neural mechanisms of probabilistic reversal learning in healthy volunteers. Many other research groups have subsequently used this paradigm to study reversal learning. Selected publications on reversal learning: 1. Cools R, Clark L, Owen AM, Robbins TW (2002). Defining the neural mechanisms of probabilistic reversal learning using event-related functional MRI. J Neurosci 22: 4563-4567. 2. Chase HW, Swainson R, Durham L, Benham L, Cools R (2011). Feedback-related